It’s been a year since the gene-editing treatment Casgevy was approved for sickle cell disease and a related blood disorder.

CRISPR Therapeutics ( CRSP -5.91%) made a name for itself by pioneering advanced gene therapies made with technologies that didn't exist a generation ago. Now, its challenge is to build on its prior ...

Using CRISPR, the popular gene-editing tool, scientists bumped up the fruit’s sugar content by 30 percent without sacrificing ...

An international research team has uncovered a new mechanism crucial to the production of cellular proteins. When this ...

Gene mutations have consequences both good and bad—from resistance to conditions like diabetes to susceptibility to certain ...

These three emerging technology leaders are pioneering quantum computing, gene editing, and electric aviation.

The Cas nuclease market is on an upward trajectory, forecasted to grow from $2.75 billion in 2023 to $3.27 billion in 2024, at a CAGR of 18.9%. Key drivers include the rapid advancements in genome ...

To separate AI hype from reality in medicine, a doctor and author of a book on generative AI’s future in medicine suggests asking three simple questions.

Cancer continues to be a formidable challenge globally, with traditional drug discovery methods focusing on cytotoxic agents and targeted therapies altering the landscape of cancer prognosis and ...

Overall, these results will be useful to the RNA community. The mRNA 5'-cap structure removal by the decapping enzyme DCP2 is a critical step in gene regulation. While DCP2 is the catalytic subunit in ...

We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands ...